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Abstract: The loss of tumour suppressor gene function is a hallmark of malignant transformation
and can occur by a variety of genetic and/or epigenetic alterations. We have previously
characterised p38δ mitogen-activated protein kinase (MAPK) as a tumour suppressor in
oesophageal squamous cell carcinoma (OESCC) and outlined how loss of p38δ MAPK expression
promotes increased proliferation and migration, as well as reduced chemosensitivity. Our aim
was to investigate the underlying molecular causes of loss of p38δ MAPK expression in OESCC.
Sequence analysis of DNA from p38δ MAPK positive and p38δ MAPK negative OESCC cell
lines was used to investigate potential loss of function causing mutations. Epigenetic control
of p38δ expression in OESCC was examined using methylation-specific PCR and sequencing of
bisulfite-converted DNA. We did not identify any mutations in the MAPK13 sequence in OESCC
cell lines which lack p38δ MAPK expression. However, we identified a differential pattern of
methylation between p38δ MAPK positive and p38δ MAPK negative cell lines. We outline here
for the first time differential MAPK13 promoter methylation in OESCC. Our results suggest that
epigenetic alterations are responsible, in part, for the suppression of p38δ MAPK expression and
promotion of tumourigenesis in OESCC.
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1. Introduction
We have previously documented the differential expression of p38δ mitogen activated protein
kinase (MAPK) in oesophageal squamous cell carcinoma (OESCC) and the consequences of
p38δ MAPK expression on OESCC tumourigenicity and response to cytotoxic drugs. Loss of
p38δ MAPK expression contributes to a pro-oncogenic phenotype in OESCC and affords a level
of resistance to conventional cisplatin and 5-fluorouracil treatment [1,2]. Re-introduction of p38δ
and p-p38δ MAPK expression resulted in a decrease in OESCC cell proliferation, migration and
anchorage-independent growth [1]. These results demonstrated significant tumour suppressive
functions for p38δ MAPK in OESCC. Loss of p38δ MAPK expression can therefore be considered
as a significant pro-survival mechanism in OESCC. In general, loss or inactivation of tumour
suppressor genes occurs via genetic changes, such as point mutations and deletions or by epigenetic
regulation [3]. This new study sheds light on some mechanism(s) by which the loss of p38δ MAPK
expression may occur in OESCC.
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At the genomic level, point mutations, insertions, and deletions of genetic material are common
mechanisms by which expression of tumour suppressor genes are inactivated. The somatic mutation
rate for OESCC is higher than in breast carcinoma, with C.G Ñ T.A transitions the most common,
followed by C.GÑG.C transversions [4,5]. Point mutations can be responsible for converting a codon
into a premature stop codon or replacing an essential amino acid thereby abolishing or reducing the
production of a functioning gene product. Point mutations can also cause aberrant RNA splicing,
again abolishing the function of the gene [6]. The tumour suppressor p53 is frequently mutated
in OESCC and p53 mutated oesophageal cancer is recognised as being resistant to conventional
chemotherapy [7,8]. Insertion or deletion of a single nucleotide can cause a frameshift in the
coding sequence which has not been explored to date as a means for explaining loss of p38δ MAPK
protein expression.
Cancer genomes are also characterised by epigenetic changes such as aberrant DNA methylation,
in addition to mutations and chromosomal abnormalities [9–11]. DNA methylation occurs in
cytosines which precede guanines i.e., CpG dinucleotides and is essential for normal maintenance of
tissue-specific gene expression [12]. In comparison with normal cells, cancer cells display global DNA
hypomethylation, particularly in repetitive DNA sequences and introns which mediates genome
instability [13–15]. This is coupled with specific hypermethylation of tumour suppressor genes
which is responsible for gene silencing as DNA methylation inhibits transcription factor binding
to promoter regions [16]. Hypermethylation of CpG-rich regions in gene promoters (known as
CpG islands) is in fact one of the most common epigenetic changes to occur in tumours. Interestingly,
it is found in almost all types of human neoplasms and gene inactivation by epigenetic silencing
is at least as common as the classic coding-region mutation based disruption of tumour suppressor
genes [17–20]. This form of epigenetic regulation is increasingly implicated in the development and
progression of many cancers, including oesophageal carcinomas where tumour suppressor genes
involved in the cell cycle, such as p16INK4b and p14ARF, are frequently hypermethylated [3,16].
Notably, promoter hypermethylation has previously been implicated in the epigenetic silencing of
p38δ MAPK in different cancer types. In malignant pleural mesothelioma and primary cutaneous
melanoma MAPK13 promoter methylation is associated with decreased p38δ MAPK mRNA and
protein expression [21,22]. Restoration of p38δ MAPK expression in melanoma cells decreases
proliferation [21].
In this study mRNA and gDNA sequences from p38δ MAPK protein positive and negative cell
lines were compared in order to identify any of the genetic abnormalities discussed above, which may
explain the differential loss of p38δ MAPK expression. Possible epigenetic regulation of p38δ MAPK
expression was investigated using methylation-specific PCR (MSP) and bisulfite sequencing PCR
(BSP) analysis of CpG islands in the MAPK13 promoter region.
2. Results and Discussion
2.1. OESCC Cell Lines Lacking Endogenous p38δMAPK Expression Proliferate and Migrate Faster than
Those Which Express This Isoform
We have previously identified that p38δ MAPK plays a key role in OESCC cell proliferation
and migration using a small number of cell lines [1]. We have now extended these earlier reports
using a larger number of cell lines lacking p38δ MAPK expression (KE-3 and -8, KYSE-70, OE-21,
and OC-1) as well as those that express p38δ MAPK (KE-4, -5, -6 and -10, KYSE-450, OC-3, OE-19,
-21, and -33). Using the trypan blue exclusion assay we compared the proliferation rate of p38δ
negative and positive oesophageal cell lines. We observed that at all time-points studied (24–120 h)
the p38δ negative OESCC cell lines grew significantly (p < 0.01) faster than the p38δ positive cell
lines (Figure 1A,B). Of note, the two p38δ positive OE-19 and OE-33 are oesophageal adenocarcinoma
cell lines and did not demonstrate a statistically significant difference in their proliferation compared
to the p38δ negative OESCC cell lines. We have previously reported that differential p38δ MAPK
expression is only observed in OESCC and not adenocarcinoma cell lines [1]. A key characteristic of
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cancer cells is their ability to migrate and progress from primary tumours to metastases in distant
organs. We examined whether the p38δ status of OESCCs could influence their rate of cell migration.
Using a Boyden Chamber assay and allowing the cells to migrate for 24 h we observed that all
five p38δ negative OESCC cells migrated significantly (p < 0.01) faster than their p38δ positive
counterparts (Figure 1C).Canc s 2015, 7, page–page     
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Figure 1. Effect of p38δ MAPK status on oesophageal cancer cell growth and migration. Oesophageal 
p38δ MAPK negative (KE-3 and -8, KYSE-70, OE-21, and OC-1) (A) and positive (KE-4, -5, -6, and -
10, KYSE-450, OC-3, OE-19, -21 and -33) (B) cell lines were examined for their cell proliferation rate. 
Cells were seeded (3 × 104) in six-well plates and counted for 24–120 h (A,B); (C) Effect of p38δ on cell 
migration using a Boyden Chamber as described in the Experimental Section. The results shown are 
mean ± S.E. of three independent experiments. 
2.2. p38δ MAPK mRNA Is Present in All OESCC Cell Lines 
Intron-spanning primer sets within the p38δ MAPK coding region amplified cDNA from p38δ 
MAPK protein positive cell lines KE-4, -5, -6 and -10, KYSE-450, OC-3, OE-19, and -33, as well as from 
p38δ MAPK protein negative cell lines OE-21 and OC-1 (Figure 2A,B). Varying levels of amplicon 
were observed from KE-3, KE-8, and KYSE-70 (p38δ MAPK protein negative) cells, depending on the 
primer pair used. Primers specific for a 1575 bp portion of p38δ mRNA (P002F and P001R) weakly 
amplified cDNA from KE-8 and KYSE-70 cells, but not from KE-3 cells (Figure 2A). PCR with a primer 
pair specific for a 1605 bp region of p38δ mRNA (P003F and P001R) did not yield any detectable 
product from KYSE-70 cDNA but did weakly amplify cDNA from KE-3 and KE-8 cells (Figure 2B). 
In the absence of any detectable mutations at the genomic level, differential p38δ MAPK mRNA 
expression was the most likely cause of p38δ MAPK protein loss. Therefore, p38δ MAPK mRNA 
expression was further analysed. Quantitive real-time PCR was used to determine the relative levels 
of p38δ MAPK mRNA expression in each of the OESCC cell lines being studied. p38δ MAPK mRNA 
expression was found to be highest in p38δ MAPK protein positive cells KE-6 and KYSE-450, 
although there was a significant (p < 0.01) difference between the two cell lines (Figure 2C). p38δ 
MAPK mRNA expression was similarily and significantly (p < 0.001) down-regulated in p38δ MAPK 
protein negative cell lines KE-3, KE-8, and KYSE-70 when compared with both KE-6 and KYSE-450 
p38δ MAPK protein positive cells (Figure 2C). OE-21 and OC-1 (both p38δ MAPK protein negative) 
demonstrated intermediate levels of p38δ MAPK mRNA expression yet still with significant (*** p < 
0.001 and ** p < 0.01) decreases from KE-6 and KYSE-450 expression (Figure 2C).  
Figure 1. Effect of p38δ MAPK status on oesophageal cancer cell growth and migration. Oesophageal
p38δ MAPK negative (KE-3 and -8, KYSE-70, OE-21, and OC-1) (A) and positive (KE-4, -5, -6, and -10,
KYSE-450, OC-3, OE-19, -21 and -33) (B) cell lines were examined for their cell proliferation rate. Cells
were seeded (3 ˆ 104) in six-well plates and counted for 24–120 h (A,B); (C) Effect of p38δ on cell
migration using a Boyden Chamber as described in the Experimental Section. The results shown are
mean ˘ S.E. of three independent experiments.
2.2. p38δMAPK mRNA Is Present in All OESCC Cell Lines
Intron-spanning primer sets within the p38δ MAPK coding region amplified cDNA from
p38δ MAPK protein positive cell lines KE-4, -5, -6 and -10, KYSE-450, OC-3, OE-19, and -33,
as well as from p38δ MAPK protein negative cell lines OE-21 and OC-1 (Figure 2A,B). Varying
levels of amplicon were observed from KE-3, KE-8, and KYSE-70 (p38δ MAPK protein negative)
cells, depending on the primer pair used. Primers specific for a 1575 bp portion of p38δ mRNA
(P002F and P001R) weakly amplified cDNA from KE-8 and KYSE-70 cells, but not from KE-3 cells
(Figure 2A). PCR with a primer pair specific for a 1605 bp region of p38δ mRNA (P003F and P001R)
did not yield any detectable product from KYSE-70 cDNA but did weakly amplify cDNA from KE-3
and KE-8 cells (Figure 2B). In the absence of any detectable mutations at the genomic level, differential
p38δ MAPK mRNA expression was the most likely cause of p38δ MAPK protein loss. Therefore,
p38δ MAPK mRNA expression was further analysed. Quantitive real-time PCR was used to
determine the relative levels of p38δ MAPK mRNA expression in each of the OESCC cell lines
being studied. p38δ MAPK mRNA expression was found to be highest in p38δ MAPK protein
positive cells KE-6 and KYSE-450, although there was a significant (p < 0.01) difference between
the two cell lines (Figure 2C). p38δ MAPK mRNA expression was similarily and significantly
(p < 0.001) down-regulated in p38δ MAPK protein negative cell lines KE-3, KE-8, and KYSE-70 when
compared with both KE-6 and KYSE-450 p38δ MAPK protein positive cells (Figure 2C). OE-21 and
OC-1 (both p38δ MAPK protein negative) demonstrated intermediate levels of p38δ MAPK mRNA
expression yet still with significant (*** p < 0.001 and ** p < 0.01) decreases from KE-6 and KYSE-450
expression (Figure 2C).
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Figure 2. p38δ MAPK mRNA expression in oesophageal cancer. (A,B) Agarose gel electrophoresis 
analysis of DNA fragments produced by PCR amplification of p38δ MAPK mRNA from p38δ MAPK 
protein positive (KE-4, KE-5, KE-6, KE-10, KYSE-450, OC-3, OE-19, OE-33) and p38δ MAPK protein 
negative (KE-3, KE-8, KYSE-70, OE-21, OC-1) oesophageal carcinoma cells with (A) P002F and P001R 
primers and (B) P003F and P001R primers; and (C) relative p38δ MAPK mRNA levels in p38δ MAPK 
protein negative OESCC cell lines KE-3, KE-8, KYSE-70, OE-21 and OC-1 were compared with p38δ 
MAPK protein positive KE-6 and KYSE-450 cells. GAPDH was measured as an internal control. 
Relative values were calculated by normalizing 2−ΔΔCT. Results shown are the mean ± S.E. of three 
independent qrt-PCR experiments. *** p < 0.001, ** p < 0.01, significant changes in p38δ MAPK 
expression from (black) KE-6 and (grey) KYSE-450 cells were determined by application of Student’s 
t-test. 
2.3. MAPK13 Promoter Is Differentially Methylated in OESCC 
As a genetic mutation had been ruled out as an explanation for the differential loss of p38δ 
MAPK in OESCC, epigenetic regulation of p38δ MAPK expression was considered. DNA 
methylation was detected by methylation-specific PCR (MSP) in KE-3, KE-8, KYSE-70, and OC-1 cells 
(Figure 3A (M)). In contrast, no substantial DNA methylation was identified in KE-6, KYSE-450, and 
OE-21 cells (Figure 3A (M)). Furthermore, unmethylated DNA was poorly amplified in KE-3, KE-8, 
Figure 2. p38δ MAPK mRNA expression in oesophageal cancer. (A,B) Agarose gel electrophoresis
analysis of DNA fragments produced by PCR amplification of p38δ APK mRNA from p38δ APK
protein positive (KE-4, KE-5, KE-6, KE-10, KYSE-450, OC-3, OE-19, OE-33) and p38δ APK protein
negative (KE-3, KE-8, KYSE-70, OE-21, OC-1) oesophageal carcinoma cells with (A) P002F and P001R
primers and (B) P003F and P001R pri ers; and (C) relative p38δ APK mRNA levels in p38δ APK
protein negative ES cell lines KE-3, KE-8, KYSE-70, OE-21 and OC-1 were compared with
p38δ MAPK protein positive KE-6 and KYSE-450 cells. GAPDH was measured as an internal control.
Relative values were calculated by normalizing 2´∆∆ . Results s o are t e ea ˘ S. . of three
independent qrt-PCR experiments. *** p 0.001, ** p 0.01, si ifica t c a es i 38δ APK
expression fr (black) KE-6 and (grey) KYSE-450 cells were determined by application of
Student1s t-test.
2.3. APK13 Promoter Is Differentially Methylated in OESCC
As a genetic mutation had been ruled out as an explanation for the differential loss of
p38δ MAPK in OESCC, epigenetic regulation of p38δ MAPK expression was considered. DNA
methylation was detected by methylation-specific PCR (MSP) in KE-3, KE-8, KYSE-70, and OC-1 cells
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(Figure 3A (M)). In contrast, no substantial DNA methylation was identified in KE-6, KYSE-450,
and OE-21 cells (Figure 3A (M)). Furthermore, unmethylated DNA was poorly amplified in KE-3,
KE-8, and KYSE-70 cells (Figure 3A (U)). This is indicative of the presence of MAPK13 promoter
hypermethylation in p38δ MAPK protein negative OESCC (with the exception of the OE-21 cell line).
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Figure 3. MAPK13 promoter methylation analysis. (A) Agarose gel electrophoresis analysis of 
MAPK13 (Methylation-Specific PCR) MSP products (p38δ MAPK protein positive cell lines, KE-6, 
KYSE-450 and p38δ MAPK protein negative cell lines, KE-3, KE-8, KYSE-70, OE-21, OC-1; (B) DNA 
sequence analysis of MAPK13 CpG island Bisulfite Sequencing PCR (BSP) products. Residues 
identical to the reference sequence (MAPK13 NC_000006.12) residue at the same position are 
represented by a point (•), residues which differ are in uppercase; and (C) representative BSP analysis 
of CpG methylation. An unmethylated cytosine is depicted as a white circle, a methylated cytosine as 
a black circle. 
Figure 3. MAPK13 promoter methylation analysis. (A) Agarose gel electrophoresis analysis
of MAPK13 (Methylation-Specific PCR) MSP products (p38δ MAPK protein positive cell lines,
KE-6, KYSE-450 and p38δ MAPK protein negative cell lines, KE-3, KE-8, KYSE-70, OE-21, OC-1;
(B) DNA sequence analysis of MAPK13 CpG island Bisulfite Sequencing PCR (BSP) products.
Residues identical to the reference sequence (MAPK13 NC_000006.12) residue at the same position
are represented by a point (bullet), residues which differ are in uppercase; and (C) representative BSP
analysis of CpG methylation. An unmethylated cytosine is depicted as a white circle, a methylated
cytosine as a black circle.
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Bisulfite sequencing PCR (BSP) was used for further validation and analysis of MAPK13
promoter methylation density in OESCC. The methylation status of four individual CpG sites within
a MAPK13 promoter region CpG island was analysed. Comparison of DNA sequence reads of PCR
products with in silico bisulfite-converted MAPK13 reference sequence (NC_000006.12) identified
differential CpG methylation in OESCC (Figure 3B). Unmethylated CpG cytosines (C) in the MAPK13
reference sequence are converted to uracil (T). Identical residues at the equivalent positions in the PCR
products indicates the CpG residue is not methylated in that particular cell line while the presence of
unconverted C residues is indicative of DNA methylation at that individual CpG site (Figure 3B).
Of the four MAPK13 promoter region CpG sites analysed by BSP, only one was found to be
methylated in KE-6 and KYSE-450 p38δ MAPK protein positive OESCCs (Figure 3B,C). Conversely,
DNA methylation was detected at all four CpG sites in KE-3, KE-8, and KYSE-70 p38δ MAPK protein
negative OESCCs (Figure 3B,C). In p38δ MAPK protein negative OE-21 and OC-1, DNA methylation
was identified at one and two CpG sites respectively (Figure 3B,C).
3. Experimental Section
Cell culture- The KE oesophageal cancer cell lines (kind gifts from Professor T. Fujii, Kurume
University School of Medicine, Japan) [23–25] as well as KYSE-70, OE-19, OE-21, and OE-33
(ATCC, Rockville, MD, USA) were cultured in RPMI-1640 supplemented with 10% FCS, 100 µg/mL
streptomycin and 100 units/mL penicillin. KE cell line features have previously been summarized by
us [1]. OC-1 and OC-3 (kind gifts from Cork Cancer Research Centre, (Biosciences Institute, National
University of Ireland, Cork, Ireland) [26] were cultured in DMEM supplemented with 10% FCS,
100 µg/mL streptomycin and 100 units/ml penicillin. KYSE-450 cells (ATCC, Rockville, MD, USA)
were maintained in 45% RPMI-1640/45% Ham1s F-12 Nutrient Mixture supplemented with 10% FCS,
100 µg/mL streptomycin and 100 units/mL penicillin.
Proliferation assay—Cells were plated at a density of 3 ˆ 104 cells/well in a six-well tissue
culture plate. Cell viability was assessed by trypan blue (0.4% w/v) exclusion assay at the indicated
times [26].
Boyden chamber cell migration assay—Cells were plated in starvation medium at a density of
3 ˆ 104 cells/well into a 96-well plate of the upper chamber. The bottom chamber contained
10% FCS as the chemoattractant. Cells were left migrate for 24 h through the matrigel filter
(8 mm). Migrated cells were treated with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (5 mg/mL) and absorbance read at 540 nm to calculate viable cell numbers as previously
described [1].
PCR—1575bp and 1605bp fragments of p38δ MAPK mRNA, corresponding to positions
111–1686 and 82–1686 respectively of NCBI Reference Sequence NM_002754.4 were amplified
from cellular cDNA using oligonucleotide primers P003F (51-CGAGATCGGGTGCCCGGGAT-31) or
P002F (51-CCGGAAAAAGGGCTTCTACAA-31) and P001R (51-CCGCCACAAGCTAAAAAGAG-31).
Quantitative rt-PCR—p38δ MAPK mRNA expression was quantitated using a Qiagen
QuantiFastr MAPK13 Probe Assay with one-step rt-PCR and simultaneous detection of GAPDH
according to manufacturer1s instructions.
Methylation analysis—The methylation status of DNA was determined using sodium bisulfite
conversion with an EpiMarkr Bisulfite Conversion Kit (New England BioLabs, Hertfordshire,
UK) according to manufacturer1s instructions. Methylation-specific PCR (MSP) is a method of
assessing the methylation status of a group of CpG sites using individual pairs of primers specific
for methylated (M) versus unmethylated (U) DNA [27]. MSP primers (Table 1) were designed
within a CpG island in the MAPK13 promoter region (NC_000006.12 36130157-36130872) with the
aid of MethPrimer, an online program for designing bisulfite-conversion-based primers [28]. For
bisulfite sequencing PCR (BSP) oligonucleotide primers 51-TTGGGAGTTGGTTAGAAATGTA-31 and
51-AACAATACTTCCCAATTCCCT-31 were designed to amplify a 270 bp fragment from bisulfite
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converted DNA. PCR products were analysed by DNA sequencing to determine the average
methylation status for each of the four CpG dinucleotides present in the amplicon.
Table 1. Primers for Methylation-Specific PCR (MSP).
Primer Sequence (51Ñ31)
M
Forward TTTGTTTGGATTTATTAGTTTCGTC
Reverse GAACCTATCCAACCCTACGCT
U
Forward GTTTGGATTTATTAGTTTTGTTGT
Reverse CAAACCTATCCAACCCTACACT
4. Conclusions
Tumour suppressor gene function can be lost in a variety of ways in order for cancer cells
to gain the capacity for uncontrolled proliferation, migration, and escape from apoptosis. These
include somatic mutations, including insertions, deletions or point mutations, and/or epigenetic
changes such as DNA methylation or histone deacetylation. p38δ MAPK displays tumour suppressor
functions in OESCC—its loss promotes proliferation, migration, anchorage-independent growth, and
resistance to conventional chemotherapy [1,2]. p38δ MAPK expression is absent at the protein level
in OESCC cell lines KE-3, KE-8, KYSE-70, OE-21, and OC-1. In this study we outlined how this
inactivation of p38δ MAPK expression may occur in OESCC.
The results presented here indicate that this loss of protein expression cannot be attributed to a
genetic mutation or deletion. p38δ MAPK mRNA is expressed in all OESCC cell lines, regardless of
p38δ MAPK protein status. However, differential mRNA expression levels were observed between
p38δ MAPK protein positive and protein negative cell lines. The highest levels of p38δ MAPK
mRNA expression were observed in p38δ protein positive cell lines KE-6 and KYSE-450. Significantly
lower levels of p38δ MAPK mRNA were detected in p38δ MAPK protein negative cell lines. This
suggests that the absence of p38δ MAPK protein expression in these cells may be attributed to
p38δ MAPK mRNA expression failing to reach the threshold required to achieve a detectable level
of protein synthesis.
Our results show that the downregulation of p38δ MAPK mRNA expression in KE-3, KE-8,
KYSE-70, and OC-1 cells is most likely associated with MAPK13 promoter hypermethylation.
The MAPK13 promoter regions of the OESCC cell lines with the lowest levels of p38δ MAPK
mRNA expression (KE-3, KE-8, and KYSE-70 p38δ protein negative cells) are highly methylated,
as demonstrated by both MSP and BSP analysis. Conversely, in p38δ MAPK protein positive
cell lines KE-6 and KYSE-450, in which p38δ MAPK mRNA expression was significantly higher
(*** p < 0.001), a decreased incidence of DNA methylation was detected by both MSP and BSP.
OC-1 cells also expressed significantly higher (*** p < 0.001) levels of p38δ MAPK mRNA than
KE-3, KE-8, and KYSE-70 cells despite the fact that they are also p38δ MAPK protein negative.
Interestingly, however, the MAPK13 promoter was also found to be hypermethylated in this cell
line when compared with p38δ MAPK protein positive cells (two CpG sites methylated versus
one CpG site methylated). The significance of these results is that there appears to be an inverse
correlation therefore between MAPK13 promoter methylation and p38δ MAPK mRNA expression
in OESCC. Of note, methylation of the specific CpG sites examined here may not be the critical
determinants of MAPK13 expression but rather these results reflect a general pattern of MAPK13
promoter methylation. This would explain why the OE21 cell line does not appear to fit this model
of p38δ MAPK epigenetic regulation—the loss of p38δ MAPK expression in the OE21 cell line may be
caused by MAPK13 promoter methylation at a critical CpG site not included in this analysis.
The implication of MAPK13 promoter methylation in promoting tumourigenesis in OESCC
could have therapeutic inferences. Epigenetic alterations, as opposed to genetic mutations can be
pharmacologically manipulated. The DNA methyltransferase inhibitor 51-aza-21-deoxycitidine (as
decitabine) is used as a treatment for myelodysplastic syndromes and leukaemia [29,30]. Potential
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lies in the combination of epigenetic and non-epigenetic therapies. The re-expression of tumour
suppressor genes by epigenetic drugs weakens the ability of cancer cells to withstand cytotoxic
treatment, thereby lowering the dose of chemotherapeutic drug required to induce cell death [31].
Another potential clinical use of the findings presented here is as a prognostic tool. DNA methylation
analysis techniques would facilitate the sensitive and quantitative detection of a hypermethylated
MAPK13 promoter in biopsy specimens. Pre-treatment identification of p38δ MAPK status may be
useful in determining the optimal treatment and predicting response in OESCC patients.
In conclusion, promoter hypermethylation of the MAPK13 gene in KE-3, KE-8, KYSE-70, and
OC-1 OESCC cells inhibits transcription of p38δ MAPK, resulting in down-regulation of p38δ MAPK
mRNA expression. This decrease in p38δ mRNA correlates with a loss of p38δ MAPK protein
expression that is associated with increased proliferation and migration in OESCC.
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